Merit Medical Systems, a leader of healthcare technology, announced that it has acquired Biolife Delaware in a merger deal through which Biolife has become a wholly-owned subsidiary of Merit. Biolife, which is based in Sarasota, Florida, manufactures unique, patented hemostatic devices under the brand names StatSeal and WoundSeal.
This aggregate transaction consideration, paid in cash and comprising the assumption of Biolife liabilities, was approximately $120 million. This strategic deal positions Merit to provide clinicians with more products designed to standardize, simplify, and minimize post-procedure care and maintenance.
Many Merit products work through small openings in the skin, requiring efficient solutions to stop bleeding, aid patient recovery, and minimize costly complications. And in such cases, StatSeal works explicitly with the patient’s blood to rapidly form a protective seal over the procedure site. Adding StatSeal to Merit’s hemostasis portfolio is intended to give healthcare partners an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology, dialysis, electrophysiology, biopsy, and drainage.
Merit believes that the acquired assets generated about $15 million of revenue over the one year ended December 31, 2024.
Advisors: Piper Sandler acted as a financial advisor to Merit. Parr Brown Gee & Loveless served as legal advisor to Merit. Nelson Mullins Riley & Scarborough served as legal advisor to Biolife.
KEY QUOTES:
“We are excited to enhance the portfolio of hemostatic solutions offered to clinicians with the acquisition of Biolife. The acquisition provides effective, differentiated, hemostatic solutions for all percutaneous devices with a broad range of clinical applications including vascular closure and indwelling catheter bleeding complications. BioLife’s StatSeal and WoundSeal products address an estimated $350M global market opportunity, are clinically validated, and will enhance our ability to deliver comprehensive solutions to our customers. Moreover, with Merit’s resources and expertise, we believe we are well positioned to further develop and expand the reach of these product lines, ultimately benefiting patients and healthcare providers globally.”
“We have updated our full-year 2025 financial guidance to include the projected impact of this acquisition from the merger effective date of May 20, 2025 to December 31, 2025 and we have reaffirmed our updated full-year 2025 financial guidance previously issued on April 24, 2025. While we anticipate the transaction will be slightly dilutive to our full-year 2025 non-GAAP profitability given the partial-year contribution, we believe the financial profile of this acquisition is very attractive and is consistent with our goal of delivering sustainable, constant currency growth, improving profitability and strong free cash flow generation. We look forward to discussing this acquisition in further detail on our second quarter earnings report on July 30, 2025.”
Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer
